Expectant management as an option for men with stage T1c prostate cancer: a preliminary study
- 1 November 1997
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 15 (6) , 364-368
- https://doi.org/10.1007/bf01300184
Abstract
The outcome of patients selecting observation of clinical stage T1c prostate cancer is unknown. A total of 101 men with clinical stage T1c prostate cancer were evaluated, counseled, and monitored in a standard fashion. Altogether, 27 men who elected observation were older and had greater co-morbidity but similar tumor characteristics as compared with 74 men who elected radical prostatectomy. In all, 9 men demonstrated clinical or biochemical evidence of progression after a mean follow-up of 23 months; 4 men who underwent radical prostatectomy had specimen-confined disease and undetectable post-operative levels of PSA. Observation appears to be a viable option for some men with clinical stage T1c prostate cancer.Keywords
This publication has 38 references indexed in Scilit:
- The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitusPublished by Elsevier ,2004
- Prospective characterization of pathological features of Prostatic Carcinomas Detected Via Serum Prostate Specific Antigen Based ScreeningJournal of Urology, 1996
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996
- Treatment of Localized Prostate Cancer in African-American Compared with Caucasian Men; Less Use of Aggressive Therapy for Comparable DiseaseMedical Care, 1995
- Quality of Life: Radical Prostatectomy Versus Radiation Therapy for Prostate CancerJournal of Urology, 1995
- Quality-of-life outcomes in men treated for localized prostate cancerJAMA, 1995
- Prostate Cancer Rates Climbed Sharply in 1990JNCI Journal of the National Cancer Institute, 1993
- Book Review Obsessive—Compulsive Disorders: Theory and management Second edition. Edited by Michael A. Jenike, Lee Baer, and William E. Minichiello. 436 pp. Chicago, Year Book, 1990. $$44.95.New England Journal of Medicine, 1991
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958